Henry Schein Q3 EPS Forecast Decreased by Leerink Partnrs

Henry Schein, Inc. (NASDAQ:HSIC - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Henry Schein in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $1.25 per share for the quarter, down from their previous estimate of $1.30. The consensus estimate for Henry Schein's current full-year earnings is $4.74 per share.

Several other research analysts have also issued reports on the stock. Wells Fargo & Company cut their target price on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Leerink Partners set a $75.00 target price on shares of Henry Schein in a research note on Monday. Barrington Research dropped their target price on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Robert W. Baird reiterated a "neutral" rating and issued a $72.00 price target (down previously from $82.00) on shares of Henry Schein in a report on Monday. Finally, Piper Sandler cut their price target on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $78.36.

Henry Schein Trading Up 0.3%

Shares of NASDAQ:HSIC traded up $0.18 during trading on Thursday, reaching $69.50. The stock had a trading volume of 1,350,486 shares, compared to its average volume of 1,744,726. The stock has a market cap of $8.46 billion, a price-to-earnings ratio of 21.72, a P/E/G ratio of 2.24 and a beta of 0.87. Henry Schein has a 52 week low of $60.56 and a 52 week high of $82.49. The firm's fifty day moving average is $71.80 and its 200 day moving average is $71.32. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.75 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. Henry Schein had a net margin of 3.21% and a return on equity of 14.87%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same period in the previous year, the firm posted $1.10 EPS. The company's revenue for the quarter was down .1% compared to the same quarter last year.

Institutional Trading of Henry Schein

Institutional investors and hedge funds have recently made changes to their positions in the business. V Square Quantitative Management LLC grew its stake in Henry Schein by 6.3% in the second quarter. V Square Quantitative Management LLC now owns 3,377 shares of the company's stock valued at $247,000 after purchasing an additional 200 shares during the last quarter. Patton Fund Management Inc. purchased a new stake in shares of Henry Schein during the second quarter worth approximately $247,000. CX Institutional increased its position in shares of Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company's stock worth $48,000 after purchasing an additional 337 shares in the last quarter. Steph & Co. purchased a new stake in shares of Henry Schein during the second quarter worth approximately $44,000. Finally, TD Private Client Wealth LLC grew its holdings in Henry Schein by 103.0% in the 2nd quarter. TD Private Client Wealth LLC now owns 668 shares of the company's stock valued at $49,000 after buying an additional 339 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.